Newsfile Corp
08 Oct 2026, 03:24 UTC · 2h ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
Impact · against what's priced in
Unicycive Therapeutics faces potential regulatory delays for its OLC drug due to alleged manufacturing oversight, which creates significant downside risk for its primary revenue catalyst. The news is material and negative, as it introduces specific claims of FDA compliance failures and lack of vendor auditing.
- UNCY−0.60
No priced-in read yet





